Subscribe

    Lisa Swanson, MD: Insights on Maximum-use of Ruxolitinib Cream in Pediatric Patients with Atopic Dermatitis

    Lisa Swanson, MD, JCAD’s Section Editor of Pediatric Dermatology, shares her thoughts on new research evaluating maximum-use conditions for topical ruxolitinib cream in pediatric patients (2 to 11 years) with atopic dermatitis.

    MORE EXPERT PERSPECTIVES IN ATOPIC DERMATITIS

    Emma Guttman-Yassky, MD: Evaluating Long-term Efficacy of Upadacitinib in Patients with Atopic Dermatitis

    Dr. Guttman-Yassky discusses a post-hoc analysis that evaluated the efficacy of upadacitinib after 140 weeks in patients with atopic dermatitis. Reference: Butler D, et al.

    PLAY

    Lisa Swanson, MD: Topical Therapies for the Treatment of Atopic Dermatitis

    Dr. Swanson discusses three nonsteroidal topicals that have been found to be highly effective in the treatment of both children and adults with atopic dermatitis.

    PLAY

    Raj Chovatiya, MD, PhD: Maintaining Optimal Treatment Targets with Upadacitinib for Patients with Atopic Dermatitis

    Dr. Chovatiya discusses a recent poster presented at the 2025 Revolutionizing Atopic Dermatitis Conference which evaluated the effectiveness of upadacitinib in achieving long-term maintenance of

    PLAY

    Diego Ruiz Dasilva, MD, FAAD: Investigating Combination Topical Ruxolitinib and Systemic Therapies for Atopic Dermatitis

    Dr. Silva discusses a real-world, retrospective safety analysis¹ presented at the 2025 Revolutionizing Atopic Dermatitis Conference that showed positive safety results as well as substantial

    PLAY

    Andrew Mastro, MS, PA-C: Managing the Psychosocial and Occupational Burden of Chronic Hand Eczema

    Andrew Mastro discusses the impact chronic hand eczema has on patients’ quality of life and provides an update on emerging treatments for the disease, such

    PLAY

    Andrew Mastro, MS, PA-C: Providing Effective Treatment for the Head-and-neck Area in Patients with Atopic Dermatitis

    Andrew Mastro discusses various challenges of treating AD in the head-and-neck area, emphasizing the importance in choosing a treatment armed with rapidity, power, and a

    PLAY

    Naiem T. Issa, MD, PhD: Mitigating Economic Impacts of Atopic Dermatitis through Effective Treatment

    Dr. Issa discusses a real-world study¹ that demonstrated a reduced need for biologic treatments, among other AD treatments, in patients treated with topical ruxolitinib cream,

    PLAY

    Diego Ruiz Dasilva, MD, FAAD: Achievement of Optimal Treatment Targets with Oral JAK Inhibition in Elderly Patients with Atopic Dermatitis

    Dr. Dasilva discusses positive results from a recent study published in the Journal of Clinical and Aesthetic Dermatology that assessed the safety and efficacy of

    PLAY

    Lisa Swanson, MD: Insights on Maximum-use of Ruxolitinib Cream in Pediatric Patients with Atopic Dermatitis

    Lisa Swanson, MD, JCAD’s Section Editor of Pediatric Dermatology, shares her thoughts on new research evaluating maximum-use conditions for topical ruxolitinib cream in pediatric patients

    PLAY

    Michael Cameron, MD, FAAD: Improving Itch and Quality of Life in Patients with Atopic Dermatitis

    Dr. Cameron discusses promising results in a treatment that combined upadacitinib and topical corticosteroids. Reference:

    PLAY

    James Song, MD: Personalizing Treatment for Atopic Dermatitis

    Looking to the future of AD treatment, Dr. Song discusses the unmet need of predicting treatment responses in patients with atopic dermatitis, with the aim

    PLAY

    Melodie Young, MSN, RN, ANP-C: Treating Pediatric Patients with Atopic Dermatitis

    Melodie Young discusses managing treatment for younger children with atopic dermatitis, emphasizing the importance of focusing on potential and probable side effects with their caregivers.

    PLAY

    James Song, MD, FAAD: Checking in on Long-term Safety Data on JAK Inhibitors for Atopic Dermatitis

    Dr. Song discusses the latest safety data on topical and oral JAK inhibitors for patients with atopic dermatitis.

    PLAY

    Melodie Young, MSN, RN, ANP-C: Practical Aspects of Treating Patients with Atopic Dermatitis

    Melodie Young discusses the logistics of gaining access to newer medications through speciality pharmacies for patients with atopic dermatitis.
    PLAY

    James Del Rosso, DO: Evaluating Effective Topical Therapies for Atopic Dermatitis

    Dr. Del Rosso discusses the current topical treatments available for patients with atopic dermatitis that have shown consistent efficacy with limited adverse events.
    PLAY

    Andrea Nguyen, PA-C, MS: Treatment Education for Patients with Atopic Dermatitis

    Andrea Nguyen, PA-C, MS, discusses how the internet and social media has contributed to more in-depth discussion with her patients regarding treatment for atopic dermatitis.
    PLAY

    Raj Chovatiya, MD, PhD: Atopic Dermatitis Patient Counseling for Moisturization

    Dr. Chovatiya discusses the effectiveness of providing a moisturizer in combination with a topical or systemic therapy to achieve clear skin regardless of disease severity.
    PLAY

    TJ Chao, PA-C: Considering Adverse Events in Patients with Atopic Dermatitis

    TJ Chao breaks down the black box warnings for ruxolitinib cream 1.5% and discusses the importance in communicating the specifics of these warnings to patients.
    PLAY

    Raj Chovatiya, MD: Key Ingredients in Moisturizers for Atopic Dermatitis

    Dr. Chovatiya reviews some of the essentials to look for in moisturizers such as a treatment that is semipermeable and has natural moisturizing factors.
    PLAY

    Raj Chovatiya, MD, PhD: Optimizing Atopic Dermatitis Treatment through Proper Moisturization

    Dr. Chovatiya discusses the benefits of a moisturization routine as a complement to all currently available therapies for patients with atopic dermatitis.
    PLAY

    TJ Chao, PA-C: Utilizing Topical Treatments for Patients with Atopic Dermatitis

    Mr. Chao discusses the reliability of ruxolitinib cream 1.5% in treating patients with atopic dermatitis. He emphasized how well it is tolerated by patients, as
    PLAY

    Matthew Zirwas, MD: Revolution of Topical Treatments in Atopic Dermatitis

    Dr. Matthew Zirwas reviews atopic dermatitis treatments that have been essential in providing immediate improvement in itch leading to a sense of control in his
    PLAY

    Jonathan I. Silverberg, MD, PhD, MPH, FAAD: Patient Counseling in Atopic Dermatitis

    Dr. Silverberg discusses how to safely counsel patients when deciding between topical versus oral JAK inhibitors for the treatment of atopic dermatitis.
    PLAY

    Peter Lio, MD, FAAD: Sustainable Improvements for Patients with Atopic Dermatitis

    Dr. Lio discusses the effects of topical ruxolitinib in his patients with atopic dermatitis, and how he incorporates this treatment into his practice.
    PLAY

    Adam Friedman, MD, FAAD: Matching Patients to the Right Treatments for Atopic Dermatitis​

    Dr. Friedman discusses how to evaluate patients with atopic dermatitis to match them with their best treatment as well as the importance of keeping a
    PLAY

    Raj Chovatiya, MD, PhD: Itch in Atopic Dermatitis

    Raj Chovatiya, MD, PhD, Director of the Center for Eczema and Itch at the Department of Dermatology at Northwestern University Feinberg School of Medicine, discusses
    PLAY

    Raj Chovatiya, MD, PhD: Explaining the Mechanisms and Advantages of JAK Inhibitors

    Raj Chovatiya, MD, PhD, Director of the Center for Eczema and Itch at the Department of Dermatology at Northwestern University Feinberg School of Medicine, discusses
    PLAY

    Peter Lio, MD: Innovations in JAK Inhibitors

    Peter Lio, MD, of Medical Dermatology Associates of Chicago in Chicago, Illinois, discusses recent innovations in atopic dermatitis therapies with regard to JAK inhibitors. Dr.
    PLAY

    JCAD

    Journal of Clinical and Aesthetic Dermatology

    Facebook-f X-twitter Instagram Linkedin

    ©2025 JCAD | The Journal of Clinical and Aesthetic Dermatology. All Rights Reserved.